Diabetic Macular Oedema
Conditions
Keywords
diabetic retinopathy, diabetic macular edema, diabetic macular oedema, near infrared light therapy
Brief summary
This pilot study aims to establish that treatment with near infrared light (NIR) reduces diabetic macular oedema in patients suffering diabetic retinopathy by exerting a positive beneficial effect at retinal cellular level.
Detailed description
This pilot study aims to establish that treatment with near infrared light (NIR) reduces diabetic macular oedema in patients suffering diabetic retinopathy by exerting a positive beneficial effect at retinal cellular level. Diabetic retinopathy is a common cause of severe loss of vision and the most common cause of blindness in individuals between the ages of 20 and 65 years in developed countries.Swelling of the central retina or macular oedema. Patients will be treated in an office clinic,three times a week for a treatment duration of 2 minutes per session, a total of 12 times over the duration of 4 weeks and will be assessed at 8 weeks to establish any change induced in retinal oedema. Safety follow up will be assessed at 3 and 6 months post treatment.
Interventions
DEVICEEllex Integre NIR laser
Each NIR light treatment will consist of a 90 second exposure of the macula of the study eye to the Ellex Integre NIR laser with the patient fixating on the central aiming beam. The laser light beam is 4.5mm in diameter with a central masked area of 1.0 mm diameter containing the central fixation target. In this way the central macula will be spared in the event of an adverse effect of the laser, which we do not anticipate. The patient will be seated at the slit lamp laser delivery system and after the eye has been dilated and anesthetised with topical eye drops a standard fundus contact lens will be placed on the eye through which the post area pole will be visualised while the treatment is delivered. There will be 12 treatments administered over a 5 week period.
Sponsors
University of Sydney
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Diabetic Macular Oedema with centre involving thickness of \>300µm 2. Age \>= 18 years 3. Diagnosis of diabetes mellitus 4. Best corrected visual acuity of 6/9 to 6/60 (letters 77- 33) 5. Intraocular pressure 6 to 25 mmHg 6. Written informed consent has been obtained.
Exclusion criteria
a) Known allergy to agents used in the study eg. fluorescein b) Women who are pregnant, nursing, or planning a pregnancy, or who are of childbearing potential and not using reliable means of contraception. A woman is considered of childbearing potential unless she is postmenopausal and without menses for 12 months or is surgically sterilised c) Loss of vision due to other causes (e.g. age related macular degeneration, myopic macular degeneration, retinal vein occlusion) d) Macular oedema due to other causes e) An ocular condition that would prevent visual acuity improvement despite resolution of oedema (such as foveal atrophy or substantial premacular fibrosis) f) Treatment with intravitreal triamcinolone acetonide (IVTA) within the last 6 months or peribulbar triamcinolone within the last 3 months, or anti vascular endothelial growth factor (VEGF) drugs: ranibizumab and aflibercept, within the last 2 months. g) Cataract surgery within the last 3 months h) Retinal laser treatment within the last 4 months i) Media opacity including cataract that already precludes adequate macular photography or cataract that is likely to require surgery within 6 months j) Intercurrent severe disease such as septicaemia, any condition which would affect follow-up or photographic documentation (e.g. geographical, psycho-social) k) History of chronic renal failure requiring dialysis or renal transplant l) Blood pressure \>180/100 m) Patient has a condition or is in a situation that in the investigator's opinion may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study \-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Measurement in Central Macular Thickness Measured by Spectral Domain Optical Coherence Tomography( OCT) at One Month | Change from baseline in central macular thickness at one month | Change in measurement( in microns) in central macular thickness as measured by Spectral Domain Optical Coherence Tomography( OCT) |
| Change in Measurement in Central Macular Thickness Measured by Spectral Domain Optical Coherence Tomography (OCT) at Two Months | Change from baseline central macular thickness at two months | Change in measurement (in microns) in central macular thickness as measured by Spectral Domain Optical Coherence Tomography (OCT) |
| Change in Total Macular Volume as Measured by Spectral Domain Optical Coherence Tomography at One Month. | Change from baseline total macular volume at one month | The change in total macular volume was taken as the difference between the total macular volume as measured by Spectral Domain Optical Coherence Tomography at 1 month and the total macular volume at baseline |
| Change in Total Macular Volume as Measured by Spectral Domain Optical Coherence Tomography at Two Months. | Change from baseline total macular volume as measured by OCT at two months | The change in total macular volume was taken as the difference between the total macular volume as measured by Spectral Domain Optical Coherence Tomography at 2 month and the total macular volume at baseline |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Logmar Best Corrected Visual Acuity (BCVA) at One Month. | Change from baseline BCVA measured at one month | Change in Logmar Best corrected visual acuity (BCVA) from 1 month to that measured at baseline |
| Change in Logmar Best Corrected Visual Acuity (BCVA) at Two Months | Change from baseline BCVA measured at two months | Change in Logmar Best corrected visual acuity (BCVA) from 2 month to that measured at baseline |
Countries
Australia
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| NIR Laser Treatment 25 Miiliwatts (mW)/cm2 Dose The Ellex Integre NIR (near Infrared Light) Laser dose of 25 milliwats(mW)/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
Ellex Integre NIR laser: Each NIR light treatment will consist of a 90 second exposure of the macula of the study eye to the Ellex Integre NIR laser with the patient fixating on the central aiming beam. The laser light beam is 4.5mm in diameter with a central masked area of 1.0 mm diameter containing the central fixation target. In this way the central macula will be spared in the event of an adverse effect of the laser, which we do not anticipate.
The patient will be seated at the slit lamp laser delivery system and after the eye has been dilated and anesthetised with topical eye drops a standard fundus contact lens will be placed on the eye through which the post area pole will be visualised while the treatment is delivered. There will be 12 treatments administered over a 5 week period. | 7 |
| NIR Laser Treatment 100mW/cm2 Dose The Ellex Integre NIR Laser dose of 100 mW/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
Ellex Integre NIR laser: Each NIR light treatment will consist of a 90 second exposure of the macula of the study eye to the Ellex Integre NIR laser with the patient fixating on the central aiming beam. The laser light beam is 4.5mm in diameter with a central masked area of 1.0 mm diameter containing the central fixation target. In this way the central macula will be spared in the event of an adverse effect of the laser, which we do not anticipate.
The patient will be seated at the slit lamp laser delivery system and after the eye has been dilated and anesthetised with topical eye drops a standard fundus contact lens will be placed on the eye through which the post area pole will be visualised while the treatment is delivered. There will be 12 treatments administered over a 5 week period. | 7 |
| NIR Laser Treatment 200mW/cm2 Dose The Ellex Integre NIR (near Infrared Light) Laser dose of 200 mW/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
Ellex Integre NIR laser: Each NIR light treatment will consist of a 90 second exposure of the macula of the study eye to the Ellex Integre NIR laser with the patient fixating on the central aiming beam. The laser light beam is 4.5mm in diameter with a central masked area of 1.0 mm diameter containing the central fixation target. In this way the central macula will be spared in the event of an adverse effect of the laser, which we do not anticipate.
The patient will be seated at the slit lamp laser delivery system and after the eye has been dilated and anesthetised with topical eye drops a standard fundus contact lens will be placed on the eye through which the post area pole will be visualised while the treatment is delivered. There will be 12 treatments administered over a 5 week period. | 7 |
| Total | 21 |
Baseline characteristics
| Characteristic | NIR Laser Treatment 100mW/cm2 Dose | NIR Laser Treatment 200mW/cm2 Dose | Total | NIR Laser Treatment 25 Miiliwatts (mW)/cm2 Dose |
|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 4 Participants | 1 Participants | 11 Participants | 6 Participants |
| Age, Categorical Between 18 and 65 years | 3 Participants | 6 Participants | 10 Participants | 1 Participants |
| Age, Continuous | 63 years | 60 years | 65 years | 73 years |
| Race and Ethnicity Not Collected | — | — | 0 Participants | — |
| Region of Enrollment Australia | 7 Participants | 7 Participants | 21 Participants | 7 Participants |
| Sex: Female, Male Female | 1 Participants | 0 Participants | 2 Participants | 1 Participants |
| Sex: Female, Male Male | 6 Participants | 7 Participants | 19 Participants | 6 Participants |
| Visual Acuity change | 64.3 letters STANDARD_DEVIATION 7.3 | 68.8 letters STANDARD_DEVIATION 13.3 | 65.9 letters STANDARD_DEVIATION 11.7 | 64.6 letters STANDARD_DEVIATION 10.8 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 7 | 0 / 7 | 0 / 7 |
| other Total, other adverse events | 7 / 7 | 4 / 7 | 6 / 7 |
| serious Total, serious adverse events | 0 / 7 | 0 / 7 | 0 / 7 |
Outcome results
Primary
Change in Measurement in Central Macular Thickness Measured by Spectral Domain Optical Coherence Tomography( OCT) at One Month
Change in measurement( in microns) in central macular thickness as measured by Spectral Domain Optical Coherence Tomography( OCT)
Time frame: Change from baseline in central macular thickness at one month
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| NIR Laser Treatment 25 Miiliwatts (mW)/cm2 Dose | Change in Measurement in Central Macular Thickness Measured by Spectral Domain Optical Coherence Tomography( OCT) at One Month | -25.2 micrometers | Standard Deviation 35.1 |
| NIR Laser Treatment 100mW/cm2 Dose | Change in Measurement in Central Macular Thickness Measured by Spectral Domain Optical Coherence Tomography( OCT) at One Month | -29.9 micrometers | Standard Deviation 38.6 |
| NIR Laser Treatment 200mW/cm2 Dose | Change in Measurement in Central Macular Thickness Measured by Spectral Domain Optical Coherence Tomography( OCT) at One Month | -58.9 micrometers | Standard Deviation 45.5 |
p-value: 0.04ANCOVA
Primary
Change in Measurement in Central Macular Thickness Measured by Spectral Domain Optical Coherence Tomography (OCT) at Two Months
Change in measurement (in microns) in central macular thickness as measured by Spectral Domain Optical Coherence Tomography (OCT)
Time frame: Change from baseline central macular thickness at two months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| NIR Laser Treatment 25 Miiliwatts (mW)/cm2 Dose | Change in Measurement in Central Macular Thickness Measured by Spectral Domain Optical Coherence Tomography (OCT) at Two Months | -52.5 micrometers | Standard Deviation 23.6 |
| NIR Laser Treatment 100mW/cm2 Dose | Change in Measurement in Central Macular Thickness Measured by Spectral Domain Optical Coherence Tomography (OCT) at Two Months | -128.6 micrometers | Standard Deviation 51.4 |
| NIR Laser Treatment 200mW/cm2 Dose | Change in Measurement in Central Macular Thickness Measured by Spectral Domain Optical Coherence Tomography (OCT) at Two Months | -114 micrometers | Standard Deviation 59.5 |
p-value: 0.04ANCOVA
Primary
Change in Total Macular Volume as Measured by Spectral Domain Optical Coherence Tomography at One Month.
The change in total macular volume was taken as the difference between the total macular volume as measured by Spectral Domain Optical Coherence Tomography at 1 month and the total macular volume at baseline
Time frame: Change from baseline total macular volume at one month
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| NIR Laser Treatment 25 Miiliwatts (mW)/cm2 Dose | Change in Total Macular Volume as Measured by Spectral Domain Optical Coherence Tomography at One Month. | 0.1 millimeter cube | Standard Deviation 0.4 |
| NIR Laser Treatment 100mW/cm2 Dose | Change in Total Macular Volume as Measured by Spectral Domain Optical Coherence Tomography at One Month. | 0 millimeter cube | Standard Deviation 0.1 |
| NIR Laser Treatment 200mW/cm2 Dose | Change in Total Macular Volume as Measured by Spectral Domain Optical Coherence Tomography at One Month. | -0.3 millimeter cube | Standard Deviation 0.4 |
p-value: 0.12ANCOVA
Primary
Change in Total Macular Volume as Measured by Spectral Domain Optical Coherence Tomography at Two Months.
The change in total macular volume was taken as the difference between the total macular volume as measured by Spectral Domain Optical Coherence Tomography at 2 month and the total macular volume at baseline
Time frame: Change from baseline total macular volume as measured by OCT at two months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| NIR Laser Treatment 25 Miiliwatts (mW)/cm2 Dose | Change in Total Macular Volume as Measured by Spectral Domain Optical Coherence Tomography at Two Months. | -0.2 millimeters cube | Standard Deviation 0.1 |
| NIR Laser Treatment 100mW/cm2 Dose | Change in Total Macular Volume as Measured by Spectral Domain Optical Coherence Tomography at Two Months. | 0.2 millimeters cube | Standard Deviation 0.7 |
| NIR Laser Treatment 200mW/cm2 Dose | Change in Total Macular Volume as Measured by Spectral Domain Optical Coherence Tomography at Two Months. | -0.2 millimeters cube | Standard Deviation 1.2 |
p-value: 0.32ANCOVA
Secondary
Change in Logmar Best Corrected Visual Acuity (BCVA) at One Month.
Change in Logmar Best corrected visual acuity (BCVA) from 1 month to that measured at baseline
Time frame: Change from baseline BCVA measured at one month
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| NIR Laser Treatment 25 Miiliwatts (mW)/cm2 Dose | Change in Logmar Best Corrected Visual Acuity (BCVA) at One Month. | 4 letters | Standard Deviation 2 |
| NIR Laser Treatment 100mW/cm2 Dose | Change in Logmar Best Corrected Visual Acuity (BCVA) at One Month. | 2 letters | Standard Deviation 4 |
| NIR Laser Treatment 200mW/cm2 Dose | Change in Logmar Best Corrected Visual Acuity (BCVA) at One Month. | 6 letters | Standard Deviation 13 |
p-value: 0.02ANCOVA
Secondary
Change in Logmar Best Corrected Visual Acuity (BCVA) at Two Months
Change in Logmar Best corrected visual acuity (BCVA) from 2 month to that measured at baseline
Time frame: Change from baseline BCVA measured at two months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| NIR Laser Treatment 25 Miiliwatts (mW)/cm2 Dose | Change in Logmar Best Corrected Visual Acuity (BCVA) at Two Months | 4 letters | Standard Deviation 6 |
| NIR Laser Treatment 100mW/cm2 Dose | Change in Logmar Best Corrected Visual Acuity (BCVA) at Two Months | -2 letters | Standard Deviation 7 |
| NIR Laser Treatment 200mW/cm2 Dose | Change in Logmar Best Corrected Visual Acuity (BCVA) at Two Months | -3 letters | Standard Deviation 9.5 |
p-value: 0.49ANCOVA